NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- Capital expenditures, 2025
- $34M
- YoY, 2025
- −11.0%
- 5-year CAGR
- +25.5%
- 10-year CAGR
- +33.2%
Capital expenditures
Capital expenditures by fiscal year
| Period | Capex | YoY |
|---|---|---|
| 2025 | $34M | −11.0% |
| 2024 | $38M | +35.0% |
| 2023 | $28M | +71.5% |
| 2022 | $17M | −29.5% |
| 2021 | $23M | +114.7% |
| 2020 | $11M | −25.9% |
| 2019 | $15M | −40.7% |
| 2018 | $25M | +257.3% |
| 2017 | $6.9M | +68.9% |
| 2016 | $4.1M | +112.4% |
| 2015 | $1.9M | +20.0% |
| 2014 | $1.6M | +195.8% |
| 2013 | $545K | −43.9% |
| 2012 | $971K | +29.5% |
| 2011 | $750K | +138.1% |
| 2010 | $315K | +800.0% |
| 2009 | $35K | — |